NTCELL® Continues to Reverse the Progression of Parkinson’s Disease – One Year after Implant
January 26 2016 - 8:54PM
Business Wire
Over a year after treatment all four patients who took part in
Living Cell Technologies Limited’s Phase I/IIa clinical study of
NTCELL® for Parkinson’s disease remain well, and at 58 weeks
post-implant there are no safety concerns.
In all four patients NTCELL treatment has stopped the
progression of Parkinson’s disease as measured by globally accepted
and validated neurological rating scales.
After 58 weeks there is a clinically and statistically
significant improvement in all the patients’ neurological score
from their pre-implant baseline. A graph of this is viewable on the
ASX website here.
Parkinson’s disease progression is measured by a neurological
rating scale, Unified Parkinson’s Disease Rating Scale (UPDRS). The
UPDRS score increases by approximately 4 to 5 points each year as
Parkinson’s disease progresses.
NTCELL’s ability to decrease UPDRS by an average of 16 points
after 58 weeks is clinically significant, representing a 3 to 4
year reversal of neurological deterioration. In the first patient
the improvement is maintained at 74 weeks after NTCELL implant.
Dr Ken Taylor, chief executive, says the sustained improvement
of the patients is pleasing, particularly as no other treatment has
been able to maintain long term reversal of the effects of
Parkinson’s disease.
“We are delighted with the continued positive outcome of the
study. It certainly adds anticipation and motivation to our
authorised Phase IIb study, which we plan to initiate on 24
February.”
The planned Phase IIb study aims to confirm the most effective
dose of NTCELL, define any placebo component of the response and
further identify the initial target Parkinson’s disease patient sub
group.
“Our goal is to obtain provisional consent and launch NTCELL as
the first disease modifying treatment for Parkinson’s disease in
2017,” says Dr Taylor.
For further information: www.lctglobal.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160126006784/en/
Media Contact:Botica Butler Raudon PartnersRachael
JoelTel: +64 9 303 3862Mobile: +64 21 403
504rachaelj@botica.co.nz
Living Cell Technologies (ASX:LCT)
Historical Stock Chart
From Nov 2024 to Dec 2024
Living Cell Technologies (ASX:LCT)
Historical Stock Chart
From Dec 2023 to Dec 2024
